Bayesian Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Bayesian Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,900	Closed	-$101K	–	279
2026 Q1	$101K	Buy	+11,900	New	+$113K	0.12%	130
2025 Q2	–	Sell	-17,000	Closed	-$125K	–	776
2025 Q1	$125K	Buy	+17,000	New	+$131K	0.02%	529
2024 Q2	–	Sell	-10,304	Closed	-$93.8K	–	989
2024 Q1	$93.8K	Buy	+10,304	New	+$73.1K	0.01%	718
2023 Q3	–	Sell	-37,400	Closed	-$193K	–	898
2023 Q2	$193K	Buy	+37,400	New	+$222K	0.02%	644
2022 Q3	–	Sell	-16,200	Closed	-$65K	–	929
2022 Q2	$65K	Buy	16,200 +2,200	+16%	+$8.31K	0.01%	708
2022 Q1	$69K	Buy	+14,000	New	+$77.6K	0.01%	717

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bayesian Capital Management's OCUL Position: Q2 2026 in Review

Bayesian Capital Management sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 11,900 shares — an estimated $101K sold.

Bayesian Capital Management first reported a position in OCUL in Q1 2022 and held it in 6 quarters. The position peaked at $193K in Q2 2023. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Bayesian Capital Management reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
Bayesian Capital Management sold 11,900 Ocular Therapeutix shares in Q2 2026, an estimated $101K.
Bayesian Capital Management first reported a position in Ocular Therapeutix in Q1 2022 and held it in 6 quarters.
Bayesian Capital Management's Ocular Therapeutix position peaked at $193K in Q2 2023.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.